sur Nanohale AG (ETR:FYB)
Formycon AG Holds Annual General Meeting 2026
Formycon AG recently concluded its Annual General Meeting (AGM) for 2026 in Munich. The Management Board provided a thorough review of the company's performance in 2025 and discussed its future strategy. Shareholders approved all agenda items with large majorities. The meeting highlighted significant progress in Formycon's biosimilar pipeline and solidified its financial foundation for growth.
The "FYB4Growth" strategy remains central, integrating geographic diversification, a comprehensive portfolio approach, and cost efficiency. A profit and loss transfer agreement was approved, aiming to optimize internal tax benefits. 62.34% of the company's share capital participated in the vote.
Detailed voting results can be found on the Formycon website. The company aims to continue its development as a profitable biosimilar leader in the industry.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Nanohale AG